Combined laser‑activated SVF and PRP remodeled spinal sclerosis via activation of Olig‑2, MBP, and neurotrophic factors and inhibition of BAX and GFAP

This study explores a new treatment for multiple sclerosis (MS) using a combination of stromal vascular fraction (SVF) and platelet-rich plasma (PRP). The researchers tested this treatment on cats with induced MS to see if it could help them recover. The results showed that the combination of SVF and PRP led to improved motor function, reduced lesion size on MRI, and positive changes in the spinal cord tissue of the treated cats. This suggests that the combined therapy could be a promising approach for treating MS. This combined therapy appears to promote tissue repair and reduce inflammation in the spinal cord, potentially offering a new avenue for managing MS and improving patient outcomes. The study suggests the combined treatment is safe and effective for multiple sclerosis.

• 1
  Combining SVF and PRP reduced lesion intensity on MRI scans and improved the physical condition of the cats.
• 2
  The treatment increased the levels of proteins Olig2 and MBP, which are associated with nerve cell repair, and decreased Bax and GFAP, associated with cell death and inflammation.
• 3
  The combination therapy led to a significant increase in neurotrophic factors (BDNF, NGF, and SDF) which promote the survival and function of neurons.